A Changing World for
Scientific Innovation

Traditional small molecules and monoclonal antibodies remain central to most portfolios, but pipeline mix is shifting toward complex modalities. Protein and peptide therapeutics are maturing, while ADCs, oligonucleotides and cell and gene therapies are expanding rapidly. As complexity grows, supplier selection increasingly favors partners with strong quality culture, safety-first infrastructure and the ability to scale specialized capabilities without compromising compliance or delivery reliability.

Global customers are increasingly adopting China+1 strategies to diversify supply chains and reduce concentration risk. This shift is being reinforced by geopolitics, resilience-led sourcing decisions and policy signals such as BIOSECURE Act momentum in the USA, prompting re-evaluation of engagement with select China-linked providers. India is positioned to benefit, supported by robust scientific talent availability and relative cost competitiveness.

As the global pharmaceutical environment evolves, USA drug pricing pressures and upcoming patent expirations are sharpening portfolio choices. Sponsors are placing greater emphasis on acquiring or in-licensing later-stage assets, driving pipeline rationalization and more selective early discovery spend. While discovery starts may slow, later-stage development programs continue to progress, sustaining demand for development and CDMO execution.

AI adoption is accelerating as sponsors seek measurable gains in speed, productivity and decision quality. Use cases now span discovery, workflow automation and GenAI-enabled documentation and QA, alongside faster design and testing cycles. In development and manufacturing, AI and IoT-enabled tools are strengthening process understanding, asset utilization and compliance controls. With the AI landscape evolving rapidly, staying current on capabilities and governance requirements is imperative.

Targeted initiatives are providing an impetus to India's life sciences ecosystem. (PLI) Production Linked Incentive schemes are supporting domestic production of critical APIs and key starting materials, improving supply resilience. (BioE3) Biotechnology for Economy, Environment and Employment and (ANRF) Anusandhan National Research Foundation are expected to strengthen innovation capacity and talent. Industry collaboration is also increasing through (IPSO) Innovative Pharmaceutical Services Organization, while Biopharma (SHAKTI) Strategy for Healthcare Advancement through Knowledge, Technology and Innovation with an INR 100 billion outlay over five years reinforces ambition to build a global biologics and biosimilars hub.

Competitive intensity is increasing as CRDMOs expand capacity and broaden service offerings, raising customer expectations on delivery performance. In parallel, policy and geopolitical uncertainty, including potential trade measures and shifting sourcing norms, is reinforcing stricter supplier qualification and greater emphasis on continuity planning.

CROs and CDMOs have traditionally competed on quality, cost and speed. Today, sustainability has become a fourth, non-negotiable factor. Investors, regulators and sponsors are raising expectations on emissions, resource efficiency and governance maturity, and partner assessments are increasingly shaped by credible targets and transparent disclosures. ESG performance is now influencing supplier qualification and long-term award decisions.